Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common sedative stop ICU delirium in heavy drinkers?

NCT ID NCT07428681

Prevention Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving lorazepam, a sedative, can prevent delirium in intensive care patients who are at high risk due to heavy alcohol use. Researchers will use a blood test (Anttila-Index) to identify these patients. The trial involves 260 adults admitted to the ICU, who will receive either lorazepam or a placebo every 6 hours for 3 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lorazepam
What this could lead to
If it works, this could provide a simple way to prevent delirium in ICU patients with a history of heavy drinking, potentially reducing complications and hospital stays.
What could go wrong
This is a single-center trial with 260 participants, so results may not apply broadly. Lorazepam is a sedative and could cause side effects like drowsiness or dependence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 260 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2027

An estimate. Start dates often move.

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Emergency/unplanned admission to the ICU * Age ≥ 18 years * ICU stay ≤ 24 hours until first study intervention * Hospital admission ≤ 24 hours before ICU admission * Anttila-Index ≥ 4 Exclusion Criteria: * Pre-existing delirium * Admission diagnosis that requires the administration of benzodiazepines (e.g. epileptic seizure) * Pre-existing therapy with benzodiazepines * Women: Pregnancy or breastfeeding * Sequelae of acute intoxication (drugs or alcohol) at time of inclusion * Hypersensitivity, allergy, or other absolute contraindication to lorazepam * Participation in another study with investigational drug within the 30 days preceding and during the present study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Delirium confusional state are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Confusion delirium

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Delirium confusional state

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.